



OUR MEMBERS SERVE 85M @ U NOOT CETS 11N R 1:48 N W I D E

725 15th Street, NW ♦ Suite 700 ♦ Washington, DC 20005 ♦ 202-393-5725 ♦ 1-888-USBLOOD ♦ FAX 202-393-1282
Web Site: <http://www.americasblood.org> ♦ e-mail: abc@americasblood.org

October 6, 2000

Docket No. 92N-0297
Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, rm. 1061
Rockville, MD 20857

Re: Docket No. 92N-0297. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements, and Administration Procedures; Public Hearing

Dear Sir/Madam:

America's Blood Centers (ABC) requests time to make a presentation at the Food and Drug Administration's (FDA) October 27th public hearing on the Prescription Drug Marketing Act. Representing ABC will be:

Jim MacPherson
Chief Executive Officer
America's Blood Centers
725 15th Street, NW, Suite 700
Washington, DC 20005
(202) 393-5725, x12

Specifically, Mr. MacPherson, on behalf of ABC, intends to address the questions on distribution of blood derivatives by blood banks and other health care entities posed by the FDA in its announcement of the hearing. In responding to these questions, ABC intends to reference its prior submissions to the agency regarding this issue (see attachments).

We would like to request approximately 10 minutes for Mr. MacPherson's presentation. We will bring copies of any handout or slides that we present for distribution to the public at the meeting.

Sincerely,

Justin Smith

Kristen Smith
Associate Director, Legislative & Public Affairs

92N-0297

APE 3

Attachments

92N-0297

APE 3



OUR MEMBERS SERVE COMMUNITIES NATIONWIDE

725 15th Street, NW ♦ Suite 700 ♦ Washington, DC 20005 ♦ 202-393-5725 ♦ 1-888-USBLOOD ♦ FAX 202-393-1282
Web Site: <http://www.americasblood.org> ♦ e-mail: abc@americasblood.org

July 3, 2000

Food and Drug Administration
Dockets Management Branch (HFA-305)
5630 Fishers Lane, Rm. 1061
Rockville, MD 20857

Re: Docket Nos. 92N-0297 and 88N-0258. Prescription Drug Marketing Act; Reopening of Administrative Record

Dear Sir/Madam:

On behalf of America's Blood Centers ("ABC") I am submitting the following comments in response to the Food and Drug Administration's ("FDA's") notice that it is delaying the effective date and reopening the administrative record regarding its final rule "Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements, and Administrative Procedures." 64 Fed. Reg. 67720 (December 3, 1999) (hereinafter the "Final Rule").

ABC is the national association of not-for-profit regional and community blood programs ("blood centers") that are responsible for collecting almost half (47 percent) of the nation's volunteer donor blood supply. Founded in 1962, ABC, through its members, is committed to ensuring the optimal supply of blood, blood components, and blood derivatives, and to fostering the development of a comprehensive range of the highest quality blood services in communities nationwide. ABC has been an active participant in FDA's Prescription Drug Marketing Act of 1987 ("PDMA") rulemaking process and welcomes this opportunity to again address the status of blood centers under the Final Rule.

Food and Drug Administration

July 3, 2000

Page 2

Currently, FDA's Final Rule prohibits blood centers from simultaneously functioning as "health care entities" and "wholesale drug distributors." As described in detail below, many blood centers have maintained these dual roles for decades and it is vital that they be permitted to continue doing so in order to fully meet the public health needs of the communities they serve. If FDA persists in its decision to prohibit any blood center from simultaneously acting as a health care entity and state licensed wholesale drug distributor, potentially serious consequences will arise from the inability of blood centers to continue operating as part of hospital-shared service organizations. See Comments submitted by individual members of ABC to the Docket. FDA has specifically invited comment on the economic and public health impact of such prohibition and ABC urges the agency to reconsider the impact the of the prohibition on blood centers and their communities and revise the Final Rule accordingly.

Brief Legal Analysis

There is no question that under the Final Rule, any full service blood center that falls within the definition of a "health care entity" will be prohibited from engaging in the wholesale distribution of blood derived products as of the delayed effective date of the Final Rule (October 1, 2001). The analysis describing that result has been fully explored by ABC in its prior submission to the PDMA

Rulemaking Docket.¹ At the heart of ABC's objection to the Final Rule is FDA's definition of a health care entity:

Health care entity means any person that provides diagnostic, medical, surgical, or dental treatment, or chronic rehabilitative care, but does not include any retail pharmacy or any wholesale distributor. *A person cannot simultaneously be a "health care entity" and a retail pharmacy or wholesale distributor.*

21 C.F.R. § 203.3(q)(emphasis supplied). ABC members fall within this definition to the extent that they provide diagnostic and therapeutic services to patients, including for example, disease marker testing, therapeutic hemapheresis, stem cell collection and processing, transfusion services and intraoperative blood salvage.

However, blood centers also act as wholesale distributors subject to FDA's final regulations "Guidelines for State Licensing of Wholesale Prescription Drug Distributors." 21 C.F.R. Part 205; 55 Fed. Reg. 38012 (September 14, 1990). Those regulations implement the provisions of PDMA requiring minimum standards, terms, and conditions for the licensing by State authorities of persons who engage in wholesale distribution in interstate commerce of prescription drugs. 21 C.F.R. § 205.2. Although FDA's State licensing guidelines specifically exempt blood and blood components intended for transfusion from the licensing requirements, FDA does not exempt all licensed blood products. For example, blood derivatives, such as anti-hemophilic factors and other blood coagulation factors,

¹ See Comments to FDA Docket No. 92N-0297 (May 31, 1994), filed under ABC's previous name, the Council of Community Blood Centers (CCBC)(copy attached).

albumin, intravenous immune globulin and alpha-1 anti-trypsin, are not exempt from PDMA. Blood centers that purchase these types of blood products from manufacturers and distribute them to the hospitals they serve have, since the early 1990's, complied with the State licensing requirements of PDMA by obtaining State wholesale distributor licenses.

The Final Rule's prohibition on health care entities maintaining wholesale distributor status will end the ability of blood centers, as they are currently organized, to distribute licensed blood products, other than those intended for transfusion, to local health care communities. ABC continues to maintain that FDA's application of that prohibition to blood centers inappropriately expands the statutory intent of PDMA. Indeed, the principal Congressional author of PDMA, Representative John Dingell (D. Mich.), recognized that FDA's prohibition could disrupt the ability of community blood centers to supply biologics sold as prescription drugs to hemophiliacs and other individuals with compromised autoimmune systems, and believed that FDA would address the issue in order to avoid such result. See Dingell Letter of May 27, 1994 (copy attached). Unfortunately, however, FDA's Final Rule continues the ban against acting both as a state-licensed wholesale drug distributor and a health care entity.

Adverse Impact on Public Health

Without relief from the Final Rule's current prohibition on simultaneously operating as a health care entity and wholesale distributor, the public health of the communities served by blood centers will be negatively

Food and Drug Administration
July 3, 2000
Page 5

impacted. For example, a 20+ year arrangement between the New York Blood Center and a hemophilia treatment center for the provision of products will be prohibited as of the effective date of the Final Rule. As detailed in a recent letter to Dr. Epstein, Director of FDA's Office of Blood Research and Review, both the ability to distribute blood derivatives and to provide health care services, even if only a small part of a blood center's operations, are vital to the public health care of the communities that blood centers serve. See Letter from ABC to Jay S. Epstein, MD (February 25, 2000)(copy attached). No PDMA purpose is served by changing the decades old ability of blood centers to distribute critical care products to patients under well established methods that have a long history of success.

Regarding their health care entity role, most blood centers provide a limited amount of blood related and health care services that fall particularly within their medical expertise to patients that are served by the hospitals in their community. Despite the limited nature of such services, they are critical to public health in that they provide patients access to a higher level of expertise than would be possible to obtain or practical to maintain at individual community hospitals. Thus, by providing for such services through a centralized blood center, the medical expertise of the blood center can be leveraged in a manner that ensures community wide access to the highest quality blood services available.

Adverse Economic Impact

Aside from the public health ramifications, ABC is concerned that forcing blood centers to chose between acting as a health care entity or a wholesale

Food and Drug Administration
July 3, 2000
Page 6

distributor will have a negative economic impact on the provision of blood services and products. While the scope of health care services currently provided by blood centers is fairly limited, they are critical to efforts to contain health costs in that they eliminate the need to duplicate such services at multiple locations. In order for hospitals to extend the same level of medical expertise with respect to blood related health care services as is currently provided by blood centers, significant additional expenditures would be required to attract and retain qualified medical personnel. The current system by which hospitals share the services provided by their community blood centers represents a much more cost efficient approach than will be dictated by FDA's Final Rule.


Economic costs associated with the distribution of blood related products will also be negatively impacted if blood centers are not able to act both as health care entities and wholesale distributors. Rather than being able to rely on the current centralized distribution system, hospitals will be required to maintain their own inventories and will bear additional storage costs. Moreover, during periods of shortage of blood related products, hoarding by individual hospitals will likely occur. Such practices result in artificially inflated prices and will likely leave some hospitals without necessary product. In contrast, the current distribution system, which relies on a centralized blood center serving more than a single community hospital, ensures that product distribution is achieved in a fair and efficient manner, and provides an objective mechanism for redistribution on an as needed basis during times of shortage.

Food and Drug Administration
July 3, 2000
Page 7

Conclusion

As described above the multiple advantages currently associated with the current distribution and shared service arrangements between hospitals and their community blood centers will be lost if blood centers are denied the ability to act as both health care entities and wholesale distributors. Rather than forcing blood centers to eliminate one or the other of such functions, or fundamentally change their business structure, ABC requests that FDA revise the Final Rule so as not to prohibit blood centers from simultaneously acting as health care entities and wholesale drug distributors. Forcing blood centers to make a Hobson's choice between these two important roles may disrupt a valuable source of products and/or services, without any corresponding public health, economic or other benefit. In lieu of such an outcome, ABC urges FDA to revise the Final Rule to accommodate the dual functions of community blood centers and the important public health needs of the communities they serve.

Sincerely,



Jim MacPherson
Executive Director, ABC

Attachments



725 15TH STREET, NW ♦ SUITE 700 ♦ WASHINGTON, DC 20005

202-393-5725 ♦ 1-888-USBLOOD ♦ FAX: 202-393-1282

Web Site: <http://www.americasblood.org> ♦ e-mail: abc@americasblood.org

OUR MEMBERS SERVE COMMUNITIES NATIONWIDE

February 25, 2000

Jay S. Epstein, MD
Director
Office of Blood Research and Review (HFM-300)
Center for Biologics Evaluation and Research
1401 Rockville Pike
Room 400N
Rockville, MD 20852-1448

Dear Dr. Epstein:

On behalf of America's Blood Centers ("ABC"), I am writing to explain why many not-for-profit regional and community blood centers consider it vital to the public health needs of the communities that they serve to remain both distributors of blood derivatives (also known as "blood products") as well as health care entities. This dual status has been part of the role of many blood centers for decades and is important to their continuing role as hospital-shared service organizations in our local communities. ABC is the national association of not-for-profit regional and community blood programs ("blood centers") responsible for providing about half of the nation's volunteer donor blood supply. Founded in 1962, ABC, through its members, is committed to ensuring the optimal supply of blood, blood components and blood derivatives, and to fostering the development of a comprehensive range of the highest quality blood services in communities nationwide.

As presently structured, a blood center's ability to carry out both its role as a wholesale distributor of blood derivatives and a health care entity will end pursuant to the final rule implementing the Prescription Drug Marketing Act ("PDMA") which takes effect on December 4, 2000. As discussed fully below, this is clearly contrary to the public health of the local communities served by blood centers.

Even more troubling is the fact that the requirement of the final rule, which provides that a licensed wholesale drug distributor cannot also be a health care entity for purposes of PDMA (21 C.F.R. § 203.3(q)), is not an explicit requirement of the statute itself. Rather, it is an administrative expansion of FDA's authority presumably intended to further Congressional intent.¹ Yet the principal Congressional author of that legislation, Representative John Dingell (D-MI), wrote to FDA on May 27, 1994 urging FDA to address the issue since FDA's proposed rule "... could create obvious difficulties for the community blood centers in this position" (see attached letter). Representative Dingell concluded his letter to FDA as follows:

¹ For a complete legal analysis, see ABC's comments submitted to the docket in this rulemaking. (These comments were filed on May 31, 1994 under ABC's previous name, the Council of Community Blood Centers ("CCBC")).

"The Subcommittee understands that the FDA intends to address this issue in order to avoid disrupting the supply of biologics sold as prescription drugs to individuals such as hemophiliacs and individuals with compromised autoimmune systems. The Subcommittee will work with you to resolve this issue so that important services are not disrupted."

The final rule unfortunately left the ban on being both a state-licensed wholesale drug distributor and a health care entity in the final rule in place.

Blood centers are hospital shared-services organizations. That means that blood centers, by design, centralize multi-faceted blood related and health services for the hospitals in a community so that such services do not have to be duplicated at each hospital, resulting in a higher quality of blood service provided to all hospitals. In this context, blood centers collect, process, store and ship blood and blood components to their hospitals. Blood and blood components are exempt from the state wholesale drug distribution requirement of PDMA. However, blood centers also purchase blood derivatives from manufacturers and distribute them to their hospitals along with blood and blood components. Many of these derivatives are manufactured from plasma that are provided by blood centers, as historically safer and more specific derivatives have replaced many of the plasma transfusions that formerly were used to treat patients in need of plasma factors. (Indeed, to help assure a community's supply for derivatives, some blood centers link the amount of derivatives from a pharmaceutical manufacturer to the amount of plasma that they supply.) Blood derivatives, such as anti-hemophilic factors and other blood coagulation factors, albumin, intravenous immune globulin and alpha-1 anti-trypsin, are not exempt from PDMA. This means for purposes of PDMA that blood centers that ship blood derivatives in interstate commerce must be state-licensed wholesale drug distributors.

Additionally, many blood centers provide health care services to patients, which includes blood centers under the definition of a health care entity. Simultaneous provision of these two services--distribution of blood derivatives and certain health care services, are not allowed by a not-for-profit blood center under the final rule.

The prohibition on being a health care entity and a wholesale drug distributor under the PDMA regulations impacts relatively small but growing and vitally important services provided by blood centers. Many hospitals rely on blood centers to carry out several critical health care functions, including:

- 1) Therapeutic hemapheresis (such as plasma exchange, photopheresis and immunoadsorption to treat various neurologic, hematologic and autoimmune diseases, and red cell exchanges in sickle cell anemia);
- 2) Therapeutic phlebotomies (for patients with hemachromatosis and other polycythemias);
- 3) Collection, processing and use of stem cells (for treatment of a variety of malignancies); and
- 4) Transfusion services (such as crossmatching services and home and outpatient transfusions, often a far lower costs and higher quality than prevailing facilities).

These health care functions are carried out by blood centers under supervision of medical experts in conjunction with the hospital and/or the patient's own physician. Since a blood center can carry out these activities for an entire or large section of its community, it provides an opportunity to share a higher level of medical expertise than may be possible for an individual hospital, especially in smaller communities. Indeed, because blood centers have such expertise, hospitals do not have to duplicate the medical expertise necessary for these types of blood-related activities, nor do patients have to seek such expertise outside their own communities. Importantly,

since all blood centers must comply with FDA's Good Manufacturing Practices ("GMPs") for the majority of its functions, these health care functions are carried out in a GMP-compliant environment.

An example of how a blood center's role as derivatives distributor and healthcare facility may be intertwined is that some centers operate the hemophilia treatment centers in their communities in conjunction with the local hemophilia society. Some of these hemophilia treatment centers have operated for many decades as the treatment for hemophilia advanced from whole plasma transfusions to cryoprecipitated antihemophilic factor to clotting factor derivatives. In this capacity, blood centers provide the clotting factors (both human and recombinant) at the lowest possible costs to patients, while also providing expert health care, education on use of the products, disposal of resulting biohazardous waste (as many of these patients are infected with HIV and/or hepatitis), and administering the products as required.

The distribution of blood derivatives is also a small but extremely valuable part of a blood center's services to the community. The distribution of these products to hospitals is done at the same time that blood and blood components are distributed. Having all blood-related products distributed by a blood center allows the hospital to manage its own inventories more carefully and to reduce storage needs.

Also of critical value to hospitals is that the blood center, as a neutral entity, is able to distribute products in short supply equitably throughout the community it serves, preventing hoarding of products by hospitals and providing for the smooth transfer of products as necessary between hospitals. This function has been especially valuable over the recent past given the critical shortages of intravenous immune globulin ("IVIG") and alpha-1 anti-trypsin. Further, the blood center's specialized medical expertise provides valuable consultative services with regard to the proper use of blood derivatives. Two examples of recent actions by a blood center dramatically highlight this point.

- 1) In providing a hemophilia factor product to a particular hospital for a specific patient, it became clear to a blood center that inordinate amounts were being distributed. The medical director at the blood center followed up with the hospital and the patient's physician. It was discovered that the patient was keeping excessive amounts of the product at home thereby increasing the risk of improper storage and, therefore, inappropriate use.
- 2) The medical director of a blood center gave a lecture to the medical staff of a major community hospital about appropriate use of a particular blood derivative. The lecture resulted in a 50% decrease in use of this product, a multi-faceted public health benefit.

These kinds of examples occur throughout blood centers. They highlight the critical role of the blood center's medical expertise and consultative role in the proper use of these products in local communities.


While neither the distribution of blood derivatives nor the provision of health care services as described above is the principal role of a blood center, each of these activities provides a vital public health service to local communities. The value of the specialized medical expertise that exists in blood centers is critical to community health care, and the ability of the blood center to provide this medical expertise is subsidized by the small margins they earn on the sale of plasma products. Such specialized medical expertise, by and large, does not exist in the majority of local hospitals. Especially for smaller hospitals, this type of expertise is often not available. Rather than promulgate a rule that weakens a blood center's ability to carry out this public health function, FDA in its role as part of the Public Health Service and the Department of Health and Human Services should be promulgating rules that encourage safer, more medically appropriate uses of blood, blood components and blood derivatives. As recognized by Representative Dingell in his letter to FDA, such FDA rules should not

Letter: Jay Epstein, MD
February 25, 2000
Page 4 of 4

inhibit blood centers from carrying out their vital community-wide distribution role generally. This is even more critical in times of shortages.

As not-for-profit hospital shared-services entities, blood centers can objectively carry out these functions with a single goal in mind: the best interests of the public health of their local communities. ABC requests that FDA revise its regulations to encourage not discourage that goal. To serve their communities, blood centers must remain able to distribute blood derivatives under appropriate wholesale pharmaceutical licenses as required by the PDMA.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jim MacPherson". The signature is fluid and cursive, with a large initial "J" and a long, sweeping underline.

Jim MacPherson
Executive Director

Attachment

CCBC

Council of Community Blood Centers

Suite 700 • 725 15th Street, N.W. • Washington, D.C. 20005
(202) 393-5725 • FAX (202) 393-1282

May 31, 1994

Dockets Management Branch (HFA-305)
Food and Drug Administration
Room 1-23
12420 Parklawn Drive
Rockville, Maryland 20857

Re: Docket No. 92N-0297

Dear Sir or Madam:

The Council of Community Blood Centers (CCBC) submits these comments in response to the Food and Drug Administration's (FDA's) proposed rule implementing the Prescription Drug Marketing Act of 1987 (PDMA), as amended. 59 Fed. Reg. 11842 (March 14, 1994).

CCBC is the national association of not-for-profit regional and community blood programs ("blood centers") responsible for collecting over 35 percent of the nation's volunteer donor blood supply. CCBC is committed to ensuring the optimal supply of blood, blood components and blood derivatives, and to fostering the development of a comprehensive range of the highest quality blood services in communities nationwide.

CCBC is writing to request that FDA redefine "health care entity" as currently proposed so as not to preclude blood centers from simultaneously acting as "wholesale distributors" under the sales restriction provision of PDMA. CCBC fears that as proposed, FDA's regulations would unintentionally and unlawfully interfere with the unique and long-standing relationship between blood centers and the local health care communities they serve. The proposal would, at best, hamper, and quite possibly destroy blood centers' distribution of the full range of available licensed blood products, to the detriment of the Nation's blood system and the public health.

BACKGROUND

Blood centers and manufacturers are the primary providers of nearly all licensed blood components and products to local health care communities. In most instances,

the relationships between the blood centers and their communities have developed and been maintained for 30 to 50 years. Originally, the close relationship between hospitals and blood centers arose because blood centers themselves, in addition to providing blood products for transfusion, handled all aspects of the processing and distribution of the plasma-based products derived from their blood donations. Consequently, hospitals came to rely on the expertise of their blood centers in fulfilling the majority of their blood product, laboratory service and expert medical consultative needs for all licensed blood products. As blood processing technology became more sophisticated, however, blood centers began selling the plasma from donations to drug manufacturers for further processing. Despite this shift in processing responsibility, hospitals and health care facilities have continued to receive the benefits of the blood centers' expertise because most blood centers have retained their role as the ultimate distributors of all licensed blood products, not just blood and blood products intended for transfusion. Such FDA-licensed products distributed by blood centers include Albumin, Immune Globulin (intravenous and intramuscular), and Antihemophilic Factor ("Factor VIII"). Blood centers also provide an increasing number of diagnostic and therapeutic services, including disease marker testing, therapeutic hemapheresis, stem cell collection and processing, transfusion services and intraoperative blood salvage, which establishes their status as "health care entities."

On March 14, 1994, FDA issued a proposed rule, "Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements, and Administrative Procedures," implementing certain sections of the PDMA, as amended, that were not previously implemented under the Federal Guidelines for State Licensing of Wholesale Prescription Drug Distributors. 59 Fed. Reg. 11842.¹ In its proposed rule, FDA's definition of a "health care entity" provides that "a person cannot simultaneously be a 'health care entity' and a retail pharmacy or wholesale distributor." Proposed 203.3(n); 59 Fed. Reg. 11842, 11863. Read in conjunction with FDA's final regulations "Guidelines for State Licensing of Wholesale Prescription Drug Distributors," 55 Fed. Reg. 38012 (September 14, 1990), FDA's proposed definition of a "health care entity" potentially places blood centers in an untenable position.

Although FDA's State licensing guidelines specifically exempted blood and blood components intended for transfusion from the licensing requirements, FDA did not exempt all licensed blood products. Consequently, blood centers that engage in the wholesale distribution of licensed blood products in interstate commerce have complied with the State licensing requirements of PDMA. Any blood center that has obtained a license is therefore a wholesale prescription drug distributor ("wholesale distributor"). Consequently, FDA's proposed prohibition on health care entities maintaining wholesale distributor status may well end the ability of blood centers to

¹Under its proposed rule, FDA would fully exempt blood and blood components for transfusion from the remaining requirements and restrictions in PDMA. FDA previously exempted such products from the state licensing of wholesale prescription drug distribution provisions in its proposed rule entitled "Applicability to Blood and Blood Components Intended for Transfusion; Guidelines for State Licensing of Wholesale Prescription Drug Distributors." 55 Fed. Reg. 38027 (September 14, 1990). See 21 C.F.R. § 205.

distribute licensed blood products, other than those intended for transfusion, to local health care communities.

CCBC believes that as currently proposed, FDA's definition of a "health care entity" contradicts Congressional intent and disregards the clear language of the statute, resulting in inappropriate restrictions being placed upon the legitimate operations of blood centers. This clearly unintended consequence would result in significant changes in the relationship between blood centers and their local health care community customers, while serving no legislative or public health purpose whatsoever.

DISCUSSION

I. FDA's Proposed Definition of "Health Care Entity" Disregards the Clear Language of the Statute

The principal Congressional goal underlying the prohibition on resales of pharmaceuticals under section 503(c) of the PDMA was to prevent fraudulent diversion of discounted pharmaceuticals into the wholesale and retail distribution system. In its proposed regulations, FDA restates the statutory restriction regarding the resale of prescription drug products. Thus, proposed section 203.20 states:

Sales restrictions.

Except as provided in §§ 203.22, 203.23, and 203.24, no person may sell, purchase, or trade or offer to sell, purchase or trade any prescription drug that was:

- (a) Purchased by a public or private hospital or other health care entity; or
- (b) Donated or supplied at a reduced price to a charitable organization.

59 Fed. Reg. 11842, 11864. Since, however, "health care entity" is not defined in the PDMA, nor anywhere else by statute or regulation, FDA proposes to define that term in section 203.3(n) as follows:

Health care entity means any person that provides diagnostic, medical, surgical, or dental treatment or chronic or rehabilitation care but does not include any retail pharmacy or any wholesale distributor. A person cannot simultaneously be a "health care entity" and a retail pharmacy or wholesale distributor.

Id. at 11863 (emphasis supplied). Unfortunately, as currently written, FDA's proposed definition of a health care entity improperly implements the sales restriction portion of the PDMA in that it fails to uphold congressional intent and specifically disregards, and therefore conflicts with, the language of the statutorily mandated exclusion contained in section 503(c)(3) of the PDMA which provides:

For purposes of this paragraph, the term "entity" does not include a wholesale distributor of drugs or a retail pharmacy licensed under state law. . . .

Contrary to FDA's suggestion in the preamble to its proposed regulations (see 59 Fed. Reg. at 11845), the above-cited language of the statute as well as the legislative history leaves no doubt that Congress clearly envisioned scenarios where a health care entity could act as a legitimate wholesale distributor, and specifically designed the statute so as not to prohibit such activity. FDA offers no substantiation for its interpretation and the language of the statute, in fact, is antithetical to FDA's views.

Despite the clear language of the statute, FDA's proposed regulation maintains that a "health care entity" may not simultaneously be a "wholesale distributor." FDA based its decision to disregard the statute on information it has "learned" (but does not make part of the record) stating in a pertinent part that:

. . . some hospitals and health care entities, including physicians, have obtained licenses as wholesale distributors in an effort to circumvent the statutory restrictions against the sale of prescription drugs by hospitals, health care entities and charitable institutions.

59 Fed Reg. 11842, 11845. Although CCBC respects FDA's motivations in attempting to prevent circumvention of the PDMA resale prohibitions, an absolute ban on entities acquiring wholesale distributor status not only goes much further than necessary to achieve that purpose, but completely ignores the explicit exemption carved out by the statute. In administering the PDMA, FDA must give effect to the unambiguously expressed intent of Congress. Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984); see also Estate of Cowart v. Nicklos Drilling Co., 112 S.Ct. 2589, 2594 (1992) (no deference will be granted to an agency position that is contrary to an intent of Congress expressed in unambiguous terms).

In addition to disregarding the clear language of the statute, FDA's proposed definition of a "health care entity" fails to comport with the agency's own interpretation of section 503(c)(3). As stated in the preamble to the proposed regulation:

FDA interprets the first clause of the last sentence of section 503(c)(3) of the act to mean that the general prohibition against drug sales by hospitals, health care entities, and charitable institutions was not intended to interfere with the operations of legitimate licensed prescription drug wholesalers and retail pharmacies.

59 Fed. Reg. at 11845 (emphasis supplied). CCBC applauds FDA's recognition regarding the clear language of the statute and appreciates FDA's concern that section 503(c)(3) of the act:

[N]ot open up a loophole for a hospital, health care entity, or charitable institution to avoid the statutory prohibition against drug sales simply by obtaining a wholesaler license.

Id. CCBC believes, however, that a clearly articulated enforcement policy would enable FDA to achieve its goal of preventing circumvention of the resale restrictions, without conflicting with the exemption provided under section 503(c)(3) of PDMA.

II. FDA's Proposed Definition of "Health Care Entity" Contradicts Congressional Intent.

A. Congressional Intent Behind the Sales Restriction Provisions

Among the purposes of PDMA was Congress' desire to eliminate the diversion submarket for prescription drugs that created an unfair form of competition for wholesale distributors and retailers who did not participate in diversionary tactics. Congress characterized the diversion submarket as the sale, barter or trade of drugs initially sold to hospitals and other health care entities at below wholesale prices. In support of its proposed definition of a "health care entity," FDA states in the preamble that:

The legislative history, which addresses Congress' concern about donation to charitable institutions and institutional discounts for hospitals and health care entities, notes that some of these institutions had been sources of unfair competition and drug diversion, and explains that the statutory prohibition against the sale of drugs donated to or acquired at a reduced price by charitable institutions or purchased by hospitals or health care entities is directed at preventing unfair profits through resales of such drugs.

59 Fed. Reg. at 11845. Although FDA has interpreted Congressional intent correctly, to the extent FDA proposes an absolute prohibition on the ability to maintain "entity" and "wholesale distributor" status simultaneously, the agency ignores the clear wording of the statute and fails to adequately address the wrongdoing that requires remedy under PDMA. In doing so, FDA denies the statutorily mandated exception under section 503(c)(3) of the sales restriction provision of PDMA which expressly sanctions the simultaneous maintenance by an entity of wholesaler distributor status. If given effect as currently proposed, FDA's definition of a health care entity would depart from and put aside the clear language of the statute. As a matter of law, FDA cannot do that. See Lynch v. Tilden Produce Co., 265 U.S. 315 (1924) (Internal Revenue regulation defining "adulterated butter" held invalid where definition conflicts with the act and the two could not be read in harmony). At most, FDA can prescribe some limits on the nature of that exception consistent with the statute and the legislative intent of the law.

The legislative history of the PDMA makes clear that the sales restrictions were intended to eliminate fraud committed against manufacturers and unfair competition,

not to prohibit legitimate wholesale distribution by health care entities.² As stated by Congress:

Section 503(c)(3) would prohibit resales of pharmaceuticals by hospitals and other health care entities or charitable organizations with certain exceptions. This provision is intended to cover resales by both for profit and nonprofit health care entities. These institutions typically receive discount prices, substantially below the average wholesale price (AWP) for pharmaceuticals, based on their status as a health care entity or charity. When hospitals or other health care entities obtain pharmaceuticals at favorable prices and then resell those drugs at a profit, they are unfairly competing with wholesalers and retailers who cannot obtain such a favorable price. Such resales defraud manufacturers, who are led to believe that the drugs are for the use of the health care entity. In any case, these resales reward the unscrupulous and penalize the otherwise honest and efficient wholesaler or retailer while fueling the diversion market.

H. Rep. No. 76, 100th Cong., 1st Sess. 12-13 (1987). FDA's proposed definition of a health care entity penalizes not only the unscrupulous but also the "otherwise honest and efficient wholesaler." Thus, as proposed, the regulation is overly broad, at odds with statutory language and intent and therefore unlawful.

In notes accompanying the PDMA, Congress included the following finding:

The bulk resale of below wholesale priced prescription drugs by health care entities, for ultimate sale at retail, helps fuel the diversion market and is an unfair form of competition to wholesalers and retailers that must pay otherwise prevailing market prices.

21 U.S.C. § 353 (note, sec. 2 (8)). That finding is consistent with repeated references in the legislative history accompanying PDMA, clarifying that Congress' primary concern regarding the resale of pharmaceuticals arose because of abuses in the system that permitted certain entities to acquire pharmaceuticals at discount (because of their special institutional status), and then resell those drugs at a profit in unfair competition with wholesale distributors and retailers not granted preferential pricing. Indeed, in speaking before the House of Representatives on the PDMA, Representative John Dingell (D-MI) stated:

The resale of prescription drugs by certain health care entities . . . which are economical only because many manufacturers sell much more cheaply to certain institutions than to wholesale customers, provide an unfair competitive advantage to any wholesaler or retailer that can obtain

²Although CCBC is obviously most concerned about the impact FDA's proposed regulation will have on blood centers, CCBC submits that the provision under PDMA section 503(c)(3) that an entity does not include a wholesale distributor or retail pharmacy, requires FDA to preserve the right of any entity to act as a wholesale distributor, consistent with the intent of PDMA.

the preferentially priced goods. Moreover, the resales may well constitute fraud against the manufacturers, especially if the health care institution is allegedly purchasing the goods for its own use.

133 Cong. Rec. H3024 (May 4, 1987). By placing an absolute prohibition on the ability of a health care entity to concurrently maintain wholesale distributor status, FDA's proposed regulation fails to consider that blood centers (as well as other entities), may purchase pharmaceuticals (i.e. licensed blood products) that are not intended for their own use and that manufacturers understand the pharmaceuticals will be resold.³ Under those circumstances, an entity may be a legitimate wholesale distributor acting in a manner that Congress in no way intended to penalize under the resale prohibitions of the PDMA and specifically exempted under section 503(c)(3). Thus, the plain meaning of section 503(c)(3) clearly shows that Congress recognized that a health care entity could be a legitimate wholesale distributor.

B. Congress Never Intended PDMA to Encompass Community Blood Centers or Licensed Blood Products

There has never been the slightest indication of any distribution abuse of the type banned under PDMA with respect to any licensed blood products, regardless of whether or not such products have been intended for transfusion. Thus, to the extent FDA's proposed definition of a health care entity prohibits blood centers from acting as wholesale distributors under all circumstances, it fails to effectuate any specified intent of Congress. Indeed, to the extent an absolute prohibition conflicts with the express exemption provided under section 503(c)(3), it directly conflicts with congressional intent.

Neither prior to consideration of PDMA, nor during the extensive Congressional investigations, was there any documented abuses that would suggest that Congress intended that blood centers be prohibited from simultaneously acting as health care entities and wholesale distributors. Moreover, Congress had no expectation that blood centers would be covered under PDMA at all. From the earliest implementation of PDMA, Representative Dingell, Chairman of the Committee and Subcommittee most directly responsible for the enactment of PDMA, sent FDA a clear message that blood products should be exempted from the requirements and restrictions of PDMA. In a September 29, 1988 letter submitted to FDA under Docket No. 88N-0258, Mr. Dingell stated:

The inclusion of blood and blood components in the Sales Restriction Section of the Act derives not from explicit language in the statute or legislative history, but rather by virtue of the fact that FDA had previously defined such products as 503(b) drugs by regulation. [21 C.F.R. 606.3(a) and (c)]

³To the extent some blood centers purchase blood products for their own use, for example where blood centers with hemophilia treatment facilities purchase Antihemophilic Factor for their own patients, manufacturers selling to the blood centers should be aware of the situation.

Indeed, nowhere in the two-volume record of the drug diversion investigation by the Subcommittee on Oversight and Investigations, the House or Senate hearings and reports, or the Floor debate is the marketing of blood and blood products even mentioned.

That FDA's attempt to prevent circumvention of the sales restrictions under PDMA is totally inappropriate in the context of blood center operations is obvious in light of the manner in which such entities act as wholesale distributors. Currently, with respect to the resale of licensed blood products, community blood centers operate in much the same manner as traditional wholesale distributors. Manufacturers grant them volume discounts with the understanding that such savings will be passed on to the hospitals, hemophilia treatment centers, and other facilities the blood centers supply. To the extent blood centers compete with wholesalers in the distribution of licensed blood products, no unfair competition exists. Furthermore, the regulatory controls exercised over all licensed blood products and the limited supply of blood available ensures that no widespread drug wholesale distribution network exists that would give rise to the abuses PDMA intended to correct. Under the current distribution system for licensed blood products it is illogical (as well as illegal) for FDA to prohibit blood centers from simultaneously acting as entities and wholesale distributors.⁴

III. Suggested Revision of FDA's Proposed Regulations That Retains FDA's Ability to Enforce the Law

Despite the clear statutory language of section 503(c)(3), establishing that entities may simultaneously act as health care entities and wholesale distributors or retail pharmacies, CCBC also recognizes that Congress did not intend that this exemption from the resale restrictions would create a loophole for entities participating in any form of prescription drug diversion. CCBC submits, however, that section 503(c)(3) of PDMA mandates a regulatory scheme be devised whereby a health care entity can operate as a wholesale distributor or retail pharmacy within lawful parameters. In other words, a health care entity may not become a licensed wholesale distributor as a "sham" to avoid the re-sales restriction. In order for FDA to accomplish its regulatory goals consistent with the statute, the agency must amend section 203.3(n) of its proposed regulations, defining a health care entity by deleting the following portions of the proposed language:

... but does not include any retail pharmacy or wholesale distributor.
A person cannot simultaneously be a "health care entity" and a retail pharmacy or wholesale distributor.

⁴CCBC continues to believe that no legitimate basis exists for distinguishing between transfusable blood products and all other licensed blood products for purposes of carving out an exemption from PDMA. As detailed in our November 13, 1990 comments submitted under Docket No. 88N-0258 (a copy of which is attached), CCBC would have FDA expand its proposed exemption from PDMA to all licensed blood products. CCBC reiterates that position and incorporates the arguments in its November 13, 1990 comments.

CCBC does not mean by this recommendation to suggest that FDA cannot enforce the sales restriction provisions of PDMA. Rather, CCBC encourages FDA to articulate, through the preamble to the final rule, the enforcement policy it intends to follow, consistent with the goals of the PDMA. Obviously, any health care entity found to be acting in a manner that violates the intent of the sales restriction provisions of PDMA (i.e. a "sham") remains subject to FDA's enforcement of the resale prohibitions, irrespective of whether the entity is also a state licensed wholesale distributor or retail pharmacy. Thus, FDA should clarify in the preamble to the final rule that any entity that defrauds a manufacturer by improperly obtaining below average wholesale prices on the basis that the prescription drugs purchased are for its own use, when such is not the case, and who then unfairly competes in the prescription drug resale market by selling those products received at below normal wholesale prices, will be subject to FDA enforcement of PDMA.

For purposes of refining its treatment of health care entities that are also licensed wholesaler distributors, CCBC points FDA to that part of the preamble to its proposed rule where the agency focuses on the improper transfer of prescription drugs, obtained at reduced prices by health care entities, to subsidiaries for resale. 59 Fed. Reg. 11842, 11846. In its description of that prohibited activity, FDA clearly recognizes the abuses PDMA's sale restrictions were intended to eliminate, i.e., resale of prescription drugs obtained at reduced price or through donations. In the same manner FDA intends to monitor those relationships, it can monitor the wholesale distribution activities of all health care entities. Nothing prohibits FDA from requiring health care entities licensed as wholesale distributors to maintain sufficient records detailing their purchase and sale of prescription drugs. This would be fully consistent with the way that PDMA and the FDA are regulating prescription drug samples. FDA could prohibit the resale of any prescription drugs purchased at below wholesale prices where such prices are obtained based solely on the status of the purchasing entity. Such regulatory controls would address Congress' concern regarding the deception of manufacturers, and would eliminate any unfair competition with traditional wholesalers, without arbitrarily proscribing the legitimate wholesale activities of honest and efficient health care entities.

Unfortunately, as currently presented, the preamble language might suggest that FDA should require a health care entity to convert its licensed drug wholesaler operations to a for-profit subsidiary. Not only would such an arbitrary rule fail to cure the conflict with the clear language of the statute detailed above, but it is not necessary for FDA to maintain full discretion to enforce the law. Blood centers should not have to restructure their corporate activities to meet an arbitrary requirement not contemplated by the statute. Rather, CCBC believes FDA should focus on whether a health care entity has obtained a State license to be a drug wholesale distributor as part of a sham for engaging in unfair competition. It is not the corporate status of the organization (profit vs. non-profit or health care entity vs. wholesale distributor) but rather the fraudulent and unfair competitive conduct of the organization that should determine compliance with the sales restrictions provisions of PDMA. Neither the statute nor the legislative history mandate such an arbitrary decision. Again, FDA must focus on conduct and intent rather than corporate status. To do otherwise is an unlawful extension of the law.

CONCLUSION

FDA's proposed definition of a "health care entity" is a matter of great significance to blood centers and the hospitals and other health care entities they serve. CCBC strongly supports FDA's ability to enforce all of the provisions of PDMA and believes that the recommendations set forth in these comments preserve that ability, while conforming to the language and intent of the statute. Ultimately, CCBC hopes that FDA realizes that no basis exists in the law for precluding a health care entity from acting as an honest and efficient wholesale distributor.

Sincerely,



William Coenen
President

Enc. Letter to Dockets, 11/13/90

SENT BY:

5-31 04 : 4:10PM :

-Porter/Novelli

1 / 2

OUR MEMBERS FIRST (PLEASE)

MAIL ROOM
ATTENTION: CLERK
FLOOR 111, 111-1111

JOHN B. DUNCAN, UICAZAM CHAIRMAN

CHARLES BROWN, OHIO
MARGARET MARCOVICZ-REZYRSKY,
PENNSYLVANIA
HENRY A. WADSWORTH, CALIFORNIA
CARROLL COLLINS, ALABAMA
RON WYDEN, OREGON
JOHN BRYANT, TEXAS

DAN SCHAEFER, COLORADO
CARLOS J. BLOODHEAD, CALIFORNIA
JOE BARTON, TEXAS
FRANK UPTON, ILLINOIS

800 P.F. STUNTZ, STAFF DIRECTOR/CLERK

U.S. House of Representatives
Subcommittee on Oversight and Investigations
of the
Committee on Energy and Commerce
Washington, DC 20515-8116

May 27, 1994

The Honorable David A. Kessler, M.D.
Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Dear Dr. Kessler:

The Food and Drug Administration recently published a proposed rule on the Prescription Drug Marketing Act of 1987 and the amendments to this statute enacted in 1992 (59 Fed. Reg. 11842, March 14, 1994). That proposed rule covers certain requirements regarding the definition of wholesale drug distributors and health care entities.

There are some instances where community blood centers function as full-service blood centers, providing therapeutic apheresis, therapeutic phlebotomies, and diagnostic blood tests for HIV and Hepatitis, as well as providing care for hemophilia. Where these full-service community blood centers are distributors of blood products, they have presumably complied with FDA regulations by registering with their respective states as wholesalers.

Nevertheless, in the FDA's recent Federal Register notice, proposed section 203.3(n) states that:

" a person cannot simultaneously be a 'health care entity' and a retail pharmacy or wholesale distributor."

This suggests that full-service blood centers that provide legitimate health care, and that have registered with their respective state as a wholesaler, would be prohibited from either providing blood components or plasma derivatives as part of their service, or providing health care or diagnostic service. This could create obvious difficulties for the community blood centers in this position.

SENT BY:

5-31-94 : 4:11PM :

-Porter/Novelli


2 / 2

The Honorable David A. Kessler, M.D.
May 27, 1994
Page 2

The Subcommittee understands that the Agency included this prohibition not to prevent community blood centers from operating as both a health care entity as well as a wholesaler, but rather to address practices by certain physicians who were abusing the existing system. Specifically, both the Department of Justice and the FDA had determined that there were practitioners operating as health care entities that were purchasing drugs at a discount and reselling them, rather than using them to treat patients.

The Subcommittee understands that the FDA intends to address this issue in order to avoid disrupting the supply of biologics sold as prescription drugs to individuals such as hemophiliacs and individuals with compromised autoimmune systems. The Subcommittee will work with you to resolve this issue so that important services are not disrupted.

Sincerely,



John D. Dingell
Chairman
Subcommittee on
Oversight and Investigations

cc: The Honorable Dan Schaefer